Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Melanoma Cases
4.2.2 Rising Governments Initiatives for Early Detection and Skin Cancer Treatment
4.2.3 Rising Technological Advancements
4.3 Market Restraints
4.3.1 High Cost Associated with the Therapy
4.3.2 Stringent Regulatory Policies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 By Diagnostics
5.1.1.1 Dermatoscopy Devices
5.1.1.2 Biopsy Devices
5.1.2 By Therapeutics
5.1.2.1 Chemotherapy
5.1.2.2 Biological Therapy
5.1.2.3 Targeted Therapy
5.1.2.4 Immune Therapy
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Diagnostics
6.1.2 Amgen, Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bayer AG
6.1.5 Bristol-Myers Squibb
6.1.6 Daiichi Sankyo Company Limited
6.1.7 F. Hoffman-La Roche Ltd.
6.1.8 GlaxoSmithKline PLC
6.1.9 Merck & Co., Inc
6.1.10 Novartis AG


7 MARKET OPPORTUNITIES AND FUTURE TRENDS